Skip to content

A randomized, Phase 1b, single-center, observer-blind, active-controlled study to evaluate the safety, immunogenicity, and immunological mechanisms of one single administration of TETRALITE influenza vaccine at two dose levels of LiteVax Adjuvant, in healthy participants aged 60 years and older and in healthy participants aged 18 to 50 years.

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2023-508230-33-00
Acronym
TETRALITE-Ib
Enrollment
70
Registered
2023-12-22
Start date
2024-01-12
Completion date
2024-10-10
Last updated
2023-12-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Influenza

Interventions

None listed

Sponsors

LiteVax B.V.
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Countries

Belgium

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026